Cognitive Augmentation Via Multimodal Sensing and Auricular Neurostimulation
Launched by OPENBCI · Jan 16, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a special type of brain stimulation can help improve thinking skills, especially when people are faced with stress or distractions. Researchers are using a head-mounted device to measure how well participants can focus and cope with challenges in a virtual reality environment. The main goal is to find out if the stimulation can enhance cognitive performance by adjusting automatically based on how stressed or distracted someone feels during the tasks.
To participate, you need to be a healthy adult between 18 and 55 years old, speak English well, and have good vision. You will take part in four virtual reality tasks designed to test your attention and response to cybersickness, which is discomfort caused by using VR. The study will compare those receiving active stimulation to those receiving a placebo (sham) stimulation to see if it makes a difference in how well you can think. It's important to note that certain medical conditions, such as a history of mental health issues or neurological disorders, may exclude you from participating. If you join, you'll be contributing to research that could help improve cognitive performance in everyday situations!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy human subjects between the ages of 18 and 55
- • Normal color vision and near visual acuity of 20/30 without correction.
- • Participant is right-hand dominant
- • Proficient in the English language
- • Ability to understand the explanations and instructions given by the study personnel
- Exclusion Criteria:
- • Participant presents current evidence of an uncontrolled and/or clinically significant medical condition or psychiatric condition
- • Participant is participating in another interventional trial within 90 days prior to or throughout duration of trial
- • Participant has a prior diagnosis of post-traumatic stress disorder, acute stress disorder, or generalized anxiety disorder
- • Participant has a diagnosis of attention deficit hyperactivity disorder (ADHD) and/or is currently taking medications for the treatment of ADHD.
- • Current or recent history of substance abuse or drug dependence including nicotine and alcohol, or use of mind-altering drugs in the past 30 days.
- • Participant has abnormal ear anatomy, ear infection present, or ear piercing that could interfere with stimulation
- • Participant has a recent history of epileptic seizures; including photosensitive epilepsy
- • Participant has a recent history of neurologic diseases or traumatic brain injury
- • Participant has presence of implanted medical devices (e.g., pacemakers, cochlear prostheses, neurostimulators)
- • Females who are pregnant or lactating
- • Participant has any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants are risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial
- • Sensitivity to bright screens or virtual reality displays
- • Recent history of neurological and psychiatric disease/disorder
About Openbci
OpenBCI is a pioneering organization dedicated to advancing the field of neuroscience through innovative technology and research. Focused on developing open-source hardware and software platforms for brain-computer interfaces and neurotechnology, OpenBCI empowers researchers and clinicians to explore the complexities of brain function and cognitive health. By facilitating access to cutting-edge tools, the organization supports a wide range of clinical trials aimed at understanding neurological disorders, enhancing brain performance, and improving mental health outcomes. OpenBCI's commitment to collaboration and transparency fosters a vibrant community of scientists, engineers, and healthcare professionals dedicated to unlocking the potential of the human brain.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brooklyn, New York, United States
Patients applied
Trial Officials
Musa Mahmood, PhD
Principal Investigator
OpenBCI
Zoe Steine-Hanson, PhD
Study Director
OpenBCI
Alejandro Covalin, PhD
Study Chair
Spark Biomedical
Navid Khodaparast, PhD
Study Chair
Spark Biomedical
Conor Russomanno, Masters
Study Chair
OpenBCI
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported